Literature DB >> 21332933

The role of the health insurance industry in perpetuating suboptimal pain management.

Michael E Schatman1.   

Abstract

BACKGROUND: Unlike pain practitioners, health care insurers in the United States are not expected to function according to a system of medical ethics. Rather, they are permitted to function under the business "ethic" of cost-containment and profitability. Despite calls for balancing the disparate agendas of stakeholders in pain management in a pluralistic system, the health insurance industry has continued to fail to take the needs of suffering chronic pain patients into consideration in developing and enacting their policies that ultimately dictate the quality and quantity of pain management services available to enrollees. This essay examined these self-serving strategies, which include failure to reimburse services and certain medications irrespective of their evidence-bases for clinical efficacy and cost-efficiency; "carving out" specific services from interdisciplinary treatment programs; and delaying and/or interrupting the provision of medically necessary treatment. Blatant and more subtle strategies utilized by insurers to achieve these ethically questionable goals are examined. Additionally, this essay addressed some of the insurance industry's efforts to delegitimize chronic pain and its treatment as a whole.
CONCLUSION: The author concludes that the outlook for chronic pain sufferers is not particularly bright, until such time that a not-for-profit single-payer system replaces the current treatment/reimbursement paradigm. Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21332933     DOI: 10.1111/j.1526-4637.2011.01061.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  15 in total

1.  The Strengths and Weaknesses of Current US Policy to Address Pain.

Authors:  Jacob Gross; Debra B Gordon
Journal:  Am J Public Health       Date:  2018-11-29       Impact factor: 9.308

2.  Prevalence and Characteristics of Chronic Spinal Pain Patients with Different Hopes (Treatment Goals) for Ongoing Chiropractic Care.

Authors:  Patricia M Herman; Sarah E Edgington; Gery W Ryan; Ian D Coulter
Journal:  J Altern Complement Med       Date:  2019-08-27       Impact factor: 2.579

3.  A practical and ethical solution to the opioid scheduling conundrum.

Authors:  Michael E Schatman; Beth D Darnall
Journal:  J Pain Res       Date:  2013-12-06       Impact factor: 3.133

4.  The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability.

Authors:  Michael E Schatman; Lynn R Webster
Journal:  J Pain Res       Date:  2015-03-18       Impact factor: 3.133

5.  The American chronic pain crisis and the media: about time to get it right?

Authors:  Michael E Schatman
Journal:  J Pain Res       Date:  2015-12-17       Impact factor: 3.133

6.  A glimmer of hope in American pain medicine?

Authors:  Michael E Schatman
Journal:  J Pain Res       Date:  2016-07-13       Impact factor: 3.133

Review 7.  Treatment Efficacy, Clinical Utility, and Cost-Effectiveness of Multidisciplinary Biopsychosocial Rehabilitation Treatments for Persistent Low Back Pain: A Systematic Review.

Authors:  Cornelia Rolli Salathé; Markus Melloh; Rebecca Crawford; Stephanie Scherrer; Norbert Boos; Achim Elfering
Journal:  Global Spine J       Date:  2018-04-19

8.  The damage done by the war on opioids: the pendulum has swung too far.

Authors:  Timothy J Atkinson; Michael E Schatman; Jeffrey Fudin
Journal:  J Pain Res       Date:  2014-05-12       Impact factor: 3.133

9.  Confronting challenges to opioid risk mitigation in the U.S. health system: Recommendations from a panel of national experts.

Authors:  Erin P Finley; Suyen Schneegans; Megan E Curtis; Vikhyat S Bebarta; Joseph K Maddry; Lauren Penney; Don McGeary; Jennifer Sharpe Potter
Journal:  PLoS One       Date:  2020-06-15       Impact factor: 3.240

10.  Fact or fiction: the truth behind the doctors company claims regarding licit and illicit opioids.

Authors:  Lisa Lynn Dragic; Jeffrey Fudin; Michael E Schatman
Journal:  J Pain Res       Date:  2018-10-11       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.